Dipòsit Digital de Documents de la UAB 10 registres trobats  La cerca s'ha fet en 0.02 segons. 
1.
13 p, 2.0 MB Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer / Garrido-Castro, Ana C. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Saura, Cristina (SOLTI Breast Cancer Research Group, Barcelona) ; Barroso-Sousa, Romualdo (Present Address: Hospital Sírio-Libanês, Brasilia, Brazil) ; Guo, Hao (Dana-Farber Cancer Institute. Division of Biostatistics, Department of Data Sciences) ; Ciruelos, Eva (Hospital 12 de Octubre (Madrid)) ; Bermejo, Begoña (CIBERONC-ISCIII. Clinic University Hospital, INCLIVA Biomedical Research Institute) ; Gavilá, Joaquin (Fundación Instituto Valenciano De Oncología) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ; Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Paré, Laia (SOLTI Breast Cancer Research Group) ; Céliz, Pamela (SOLTI Breast Cancer Research Group) ; Villagrasa, Patricia (SOLTI Breast Cancer Research Group) ; Li, Yisheng (The University of Texas MD Anderson Cancer Center. Department of Biostatistics, Division of Basic Sciences) ; Savoie, Jennifer (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Xu, Zhan (Northern Arizona University. School of Communication) ; Arteaga, Carlos L. (UT Southwestern Medical Center. Harold C. Simmons Comprehensive Cancer Center) ; Krop, Ian E. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Solit, David B. (Memorial Sloan Kettering Cancer Center. Kravis Center for Molecular Oncology) ; Mills, Gordon B. (The University of Texas MD Anderson Cancer Center. Present Address: Division of Basic Science Research, Department of Systems Biology) ; Cantley, Lewis C. (Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College) ; Winer, Eric P. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Lin, Nancy U. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Rodon, Jordi (The University of Texas MD Anderson Cancer Center. Present Address: Department of Investigational Cancer Therapeutics) ; Universitat Autònoma de Barcelona
Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. [...]
2020 - 10.1186/s13058-020-01354-y
Breast cancer research, Vol. 22 (november 2020)  
2.
16 p, 2.3 MB Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer / Palomeras, S. (Universitat de Girona. Departament de Ciències Mèdiques) ; Diaz-Lagares, Á. (University Clinical Hospital of Santiago(CHUS/SERGAS)) ; Viñas, G. (Institut d'Investigació Biomèdica (Girona)) ; Setien, F. (Hospital Universitari de Bellvitge) ; Ferreira, H.J. (Hospital Universitari de Bellvitge) ; Oliveras, G. (Hospital Universitari de Girona Doctor Josep Trueta) ; Crujeiras, A.B. (CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn)) ; Hernández, A. (Institut Català d'Oncologia) ; Lum, D.H. (University of Utah. Huntsman Cancer Institute) ; Welm, A.L. (University of Utah. Huntsman Cancer Institute) ; Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Puig, T. (Universitat de Girona. Departament de Ciències Mèdiques) ; Universitat Autònoma de Barcelona
Background: Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology. [...]
2019 - 10.1186/s13058-019-1160-x
Breast cancer research, Vol. 21 Núm. 1 (may 2019) , p. 79  
3.
7 p, 15.8 MB Study of breast cancer incidence in patients of lymphangioleiomyomatosis / Nuñez, Olivier (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ; Román, Antonio (Román Broto) (Hospital Universitari Vall d'Hebron) ; Johnson, Simon R. (National Centre for Lymphangioleiomyomatosis, Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, UK Division of Respiratory Medicine and Respiratory Research Unit, University of Nottingham) ; Inoue, Yoshikazu (National Hospital Organization Kinki-Chuo Chest Medical Center) ; Hirose, Masaki (National Hospital Organization Kinki-Chuo Chest Medical Center) ; Casanova, Álvaro (Department of Pneumology, Henares Hospital) ; de Garibay, Gorka Ruiz (ProCURE, Breast Cancer and Systems Biology, Catalan Institute of Oncology (ICO) Institute for Biomedical Research (IDIBELL)) ; Herranz-Ors, C. (Institut d'Investigació Biomèdica de Bellvitge) ; Bueno-Moreno, Gema (MD Anderson International Foundation) ; Boni, Jacopo (ProCURE, Breast Cancer and Systems Biology, Catalan Institute of Oncology (ICO) for Biomedical Research (IDIBELL), Gran via 199, L'Hospitalet del Llobregat) ; Mateo, Francesca (Institut d'Investigació Biomèdica de Bellvitge) ; Petit Montserrat, Anna (Institut d'Investigació Biomèdica de Bellvitge) ; Climent, Fina (Institut d'Investigació Biomèdica de Bellvitge) ; Soler, Teresa (Institut d'Investigació Biomèdica de Bellvitge) ; Vidal, August (Institut d'Investigació Biomèdica de Bellvitge) ; Sánchez-Mut, José Vicente (Cancer Epigenetics and Biology Program, IDIBELL) ; Esteller, Manel (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; López, José Ignacio (Cruces University Hospital, BioCruces Research Institute, University of the Basque Country) ; García, Nadia (ProCURE, Breast Cancer and Systems Biology, Catalan Institute of Oncology (ICO)Institute for Biomedical Research (IDIBELL), Gran via 199) ; Gumà, Anna (Institut d'Investigació Biomèdica de Bellvitge) ; Ortega, Raúl (Institut d'Investigació Biomèdica de Bellvitge) ; Plà, María Jesús (Institut d'Investigació Biomèdica de Bellvitge) ; Campos, Miriam (Breast Cancer Functional Unit, Department of Medical Oncology, ICO, IDIBELL) ; Ansótegui, Emilio (Lung Transplant and Cystic Fibrosis Unit, Hospital Universitario y Politecnico La Fe) ; Molina-Molina, María (Consortium for Biomedical Research in Respiratory Diseases (CIBERES), 28029 Madrid, Spain) ; Valenzuela, Claudia (Department of Pneumology, Instituto de Investigación Sanitaria La Princesa) ; Ussetti, Piedad (Department of Pneumology, University Hospital Clínica Puerta del Hierro) ; Laporta, Rosalía (Department of Pneumology, University Hospital Clínica Puerta del Hierro) ; Ancochea, Julio (Department of Pneumology, Instituto de Investigación Sanitaria La Princesa, Hospital La Princesa) ; Xaubet, Antoni (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Pollán, Marina (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ; Pujana, Miguel Angel (Institut d'Investigació Biomèdica de Bellvitge) ; Universitat Autònoma de Barcelona. Departament de Medicina
The online version of this article (doi:10. 1007/s10549-016-3737-8) contains supplementary material, which is available to authorized users.
2016 - 10.1007/s10549-016-3737-8
Breast Cancer Research and Treatment, Vol. 156 (march 2016) , p. 195-201  
4.
13 p, 2.7 MB Breast primary epithelial cells that escape p16-dependent stasis enter a telomere-driven crisis state / Feijoo, Purificación (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Terradas, Mariona (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Soler, David (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Domínguez, Daniel (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Tusell Padrós, Laura (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Genescà, A. (Anna) (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Breast cancer is the most common malignant disease in women, but some basic questions remain in breast cancer biology. To answer these, several cell models were developed. Recently, the use of improved cell-culture conditions has enabled the development of a new primary cell model with certain luminal characteristics. [...]
2016 - 10.1186/s13058-015-0667-z
Breast cancer research, Vol. 18 (January 2016) , art. 7  
5.
12 p, 471.1 KB Quantification of HER family receptors in breast cancer / Nuciforo, Paolo (Hospital Universitari Vall d'Hebron) ; Radosevic-Robin, Nina (Jean Perrin Comprehensive Cancer Center) ; Ng, Tony (University College London. UCL Cancer Institute) ; Scaltriti, Maurizio (Memorial Sloan Kettering Cancer Center) ; Universitat Autònoma de Barcelona
he clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification of patients eligible for targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) assays are routinely used to select patients to receive trastuzumab, both assays only partially predict response to the drug. [...]
2015 - 10.1186/s13058-015-0561-8
Breast cancer research, Vol. 17 (april 2015)  
6.
6 p, 394.6 KB PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer / Prat, A. (Universitat Autònoma de Barcelona. Departament de Medicina) ; Parker, J. S. (Lineberger Comprehensive Cancer Center, University of North Carolina, CB# 7295, Chapel Hill, NC 27599 USA) ; Fan, C. (Lineberger Comprehensive Cancer Center, University of North Carolina, CB# 7295, Chapel Hill, NC 27599 USA) ; Perou, C. M. (Department of Pathology & Laboratory Medicine, University of North Carolina, Chapel Hill, NC USA)
The online version of this article (doi:10. 1007/s10549-012-2143-0) contains supplementary material, which is available to authorized users.
2012 - 10.1007/s10549-012-2143-0
Breast Cancer Research and Treatment, Vol. 135 (july 2012) , p. 301-306  
7.
14 p, 2.9 MB Exploring the link between MORF4L1 and risk of breast cancer / Martrat, Griselda (Institut d'Investigació Biomèdica de Bellvitge) ; Maxwell, Christopher A. (Institut d'Investigació Biomèdica de Bellvitge) ; Tominaga, Emiko (The University of Texas Health Science Center at San Antonio) ; Porta de la Riva, Montserrat (Institut d'Investigació Biomèdica de Bellvitge) ; Bonifaci, Núria (Institut d'Investigació Biomèdica de Bellvitge) ; Gomez-Baldo, Laia (Institut d'Investigació Biomèdica de Bellvitge) ; Bogliolo, Massimo (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Lazaro, Conxi (Institut d'Investigació Biomèdica de Bellvitge) ; Blanco Guillermo, Ignacio (Institut d'Investigació Biomèdica de Bellvitge) ; Brunet, Joan (Hospital Universitari de Girona Doctor Josep Trueta) ; Aguilar, Helena (Institut d'Investigació Biomèdica de Bellvitge) ; Fernandez-Rodriguez, Juana (Hospital Universitari de Girona Doctor Josep Trueta) ; Seal, Sheila (Institute of Cancer Research (Sutton, Regne Unit)) ; Renwick, Anthony (Institute of Cancer Research (Sutton, Regne Unit)) ; Rahman, Nazneen (Institute of Cancer Research (Sutton, Regne Unit)) ; Kühl, Julia (University of Würzburg. Department of Human Genetics (Würzburg, Alemanya)) ; Neveling, Kornelia (University of Würzburg. Department of Human Genetics (Würzburg, Alemanya)) ; Schindler, Detlev (University of Würzburg. Department of Human Genetics (Würzburg, Alemanya)) ; Ramírez de Haro, Ma. José (María José) (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Castellà, María (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Hernández Viedma, Gonzalo (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Easton, Douglas F. (University of Cambridge. Department of Public Health and Primary Care) ; Peock, Susan (University of Cambridge. Department of Public Health and Primary Care) ; Cook, Margaret (University of Cambridge. Department of Public Health and Primary Care) ; Oliver, Clare T. (University of Cambridge. Department of Public Health and Primary Care) ; Frost, Debra (University of Cambridge. Department of Public Health and Primary Care) ; Platte, Radka (University of Cambridge. Department of Oncology) ; Evans, D. Gareth (Central Manchester University Hospitals NHS Foundation Trust (Manchester, Regne Unit)) ; Lalloo, Fiona (Central Manchester University Hospitals NHS Foundation Trust (Manchester, Regne Unit)) ; Eeles, Rosalind (The Institute of Cancer Research (Sutton, Regne Unit)) ; Izatt, Louise (Guy's and St Thomas NHS Foundation Trust (Londres, Regne Unit)) ; Chu, Carol (Yorkshire Regional Genetics Service (Leeds, Regne Unit)) ; Davids, Rosemarie (Ferguson-Smith Centre for Clinical Genetics (Glasgow, Regne Unit)) ; Ong, Kai-Ren (Birmingham Women's Hospital Healthcare NHS Trust (Birmingham, Regne Unit)) ; Cook, Jackie (Sheffield Children's Hospital (Sheffield, Regne Unit)) ; Douglas, Fiona (Newcastle Upon Tyne Hospitals NHS Trust (Newcastle, Regne Unit)) ; Hodgson, Shirley (University of London. St George's Hospital. Clinical Genetics Department) ; Brewer, Carole (Royal Devon & Exeter Hospital (Exeter, Regne Unit)) ; Morrison, Patrick J. (Northern Ireland Regional Genetics Centre (Belfast, Regne Unit)) ; Porteous, Mary (South East of Scotland Regional Genetics Service (Edimburg, Regne Unit)) ; Peterlongo, Paolo (Fondazione IRCCS Istituto Nazionale Tumori (Milà, Itàlia)) ; Manoukian, Siranoush (Fondazione IRCCS INT (Milà, Itàlia)) ; Peissel, Bernard (Fondazione IRCCS INT (Milà, Itàlia)) ; Zaffaroni, Daniela (Fondazione IRCCS INT (Milà, Itàlia)) ; Roversi, Gaia (Fondazione IRCCS INT (Milà, Itàlia)) ; Barile, Monica (Istituto Europeo di Oncologia (Milà, Itàlia)) ; Viel, Alessandra (Centro di Riferimento Oncologico (Aviano, Itàlia)) ; Pasini, Barbara (University of Turin. Department of Genetics, Biology and Biochemistry (Torí, Itàlia)) ; Ottini, Laura (Sapienza University of Rome. Department of Molecular Medicine) ; Putignano, Anna Laura (University of Florence. Department of Clinical Physiopathology (Florència, Itàlia)) ; Savarese, Antonella (Regina Elena Cancer Institute (Roma, Itàlia)) ; Bernard, Loris (IEO. Department of Experimental Oncology (Milà, Itàlia)) ; Radice, Paolo (Fondazione IRCCS Istituto Nazionale Tumori (Milà, Itàlia)) ; Healey, Sue (Queensland Institute of Medical Research. Division of Genetics and Population Health (Brisbane, Austràlia)) ; Spurdle, Amanda (Queensland Institute of Medical Research. Division of Genetics and Population Health (Brisbane, Austràlia)) ; Chen, Xiaoqing (Queensland Institute of Medical Research. Division of Genetics and Population Health (Brisbane, Austràlia)) ; Beesley, Jonathan (Queensland Institute of Medical Research. Division of Genetics and Population Health (Brisbane, Austràlia)) ; Rookus, Matti A. (The Netherlands Cancer Institute. Department of Epidemiology (Amsterdam, Països Baixos)) ; Verhoef, Senno (The Netherlands Cancer Institute. Family Cancer Clinic (Amsterdam, Països Baixos)) ; Tilanus-Linthorst, Madeleine A. (Erasmus MC-Daniel den Hoed Cancer Center (Rotterdam, Països Baixos)) ; Vreeswijk, Maaike P. (Leiden University Medical Center. Center for Human and Clinical Genetics (Leiden, Països Baixos)) ; Asperen, Christi J. (Leiden University Medical Center. Center for Human and Clinical Genetics (Leiden, Països Baixos)) ; Bodmer, Danielle (Radboud University Nijmegen Medical Center. Department of Human Genetics (Nijmegen, Països Baixos)) ; Ausems, Margreet G. E. M. (University Medical Center Utrecht. Department of Medical Genetics (Utrecht, Països Baixos)) ; van Os, Theo A. (Academic Medical Center, Department of Clinical Genetics (Amsterdam, Països Baixos)) ; Blok, Marinus J. (University Hospital Maastricht. Department of Clinical Genetics (Maastricht, Països Baixos)) ; Meijers-Heijboer, Hanne E. J. (VU Medical Center. Department of Clinical Genetics (Amsterdam, Països Baixos)) ; Hogervorst, Frans B. L. (The Netherlands Cancer Institute. Family Cancer Clinic (Amsterdam, Països Baixos)) ; Goldgar, David E. (University of Utah School of Medicine. Department of Dermatology (Salt Lake City, Estats Units d'Amèrica)) ; Buys, Saundra (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ; John, Esther M. (Cancer Prevention Institute of California (Fremont, Estats Units d'Amèrica)) ; Miron, Alexander (Dana-Farber Cancer Institute. Department of Cancer Biology (Boston, Estats Units d'Amèrica)) ; Southey, Melissa (The University of Melbourne. Melbourne School of Population Health (Austràlia)) ; Daly, Mary B. (Fox Chase Cancer Center. Division of Population Science (Philadelphia, Estats Units d'Amèrica)) ; Harbst, Katja (Lund University. Department of Oncology (Lund, Suècia)) ; Borg, Åke (Lund University. Department of Oncology (Lund, Suècia)) ; Rantala, Johanna (Karolinska University Hospital. Department of Clinical Genetics (Estocolm, Suècia)) ; Barbany-Bustinza, Gisela (Karolinska University Hospital. Department of Clinical Genetics (Estocolm, Suècia)) ; Ehrencrona, Hans (Uppsala University. Departament of Genetics and Pathology (Uppsala, Suècia)) ; Stenmark-Askmalm, Marie (Hälsouniversitetet Universitetssjukhuset. Department of Oncology (Linköping, Suècia)) ; Kaufman, Bella (Chaim Sheba Medical Center. The Institute of Oncology (Ramat Gan, Israel)) ; Laitman, Yael (Chaim Sheba Medical Center. The Susanne Levy Gertner Oncogenetics Unit (Ramat Gan, Israel)) ; Milgrom, Roni (Chaim Sheba Medical Center. The Susanne Levy Gertner Oncogenetics Unit (Ramat Gan, Israel)) ; Friedman, Eitan (Chaim Sheba Medical Center. The Susanne Levy Gertner Oncogenetics Unit (Ramat Gan, Israel)) ; Domchek, Susan M. (University of Pennsylvania School of Medicine. Abramson Cancer Center (Philadelphia, Estats Units d'Amèrica)) ; Nathanson, Katherine L. (University of Pennsylvania School of Medicine. Abramson Cancer Center (Philadelphia, Estats Units d'Amèrica)) ; Rebbeck, Timothy R. (University of Pennsylvania School of Medicine. Abramson Cancer Center (Philadelphia, Estats Units d'Amèrica)) ; Johannsson, Oskar Thor (20A Landspitali-LSH v/Hringbraut. Department of Oncology (Reykjavik, Islàndia)) ; Couch, Fergus J. (Mayo Clinic. Department of Laboratory Medicine and Pathology (Rochester, Estats Units d'Amèrica)) ; Wang, Xianshu (Mayo Clinic. Department of Laboratory Medicine and Pathology (Rochester, Estats Units d'Amèrica)) ; Fredericksen, Zachary (Mayo Clinic. Department of Health Sciences Research (Rochester, Estats Units d'Amèrica)) ; Cuadras, Daniel (Institut d'Investigació Biomèdica de Bellvitge) ; Moreno, Víctor (South East of Scotland Regional Genetics Service, Western General Hospital (Edimburg, Regne Unit)) ; Pientka, Friederike K. (University of Lübeck. Center for Structural and Cell Biology in Medicine (Lübeck, Alemanya)) ; Depping, Reinhard (University of Lübeck. Center for Structural and Cell Biology in Medicine (Lübeck, Alemanya)) ; Caldés, Trinidad (Hospital Clínico San Carlos (Madrid)) ; Osorio, Ana (Spanish National Cancer Research Centre. Human Cancer Genetics Programme (Madrid, Espanya)) ; Benítez, Javier (Spanish National Cancer Research Centre. Human Cancer Genetics Programme (Madrid, Espanya)) ; Bueren, Juan (Centro de Investigaciones Energéticas, Medioambientales, y Tecnológicas (Madrid, Espanya)) ; Heikkinen, Tuomas (Helsinki University Central Hospital. Department of Obstetrics and Gynecology (Helsinki, Finlàndia)) ; Surrallés i Calonge, Jordi (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Pujana, Miguel Angel (Institut d'Investigació Biomèdica de Bellvitge) ; Tominaga, Kaoru (The University of Texas Health Science Center at San Antonio) ; Cerón, Julián (Institut d'Investigació Biomèdica de Bellvitge) ; Antoniou, Antonis C. (University of Cambridge. Department of Public Health and Primary Care) ; Fert Ferrer, Sandra (Hôtel Dieu Centre Hospitalier (Chambéry, França)) ; Collonge-Rame, Marie-Agnès (Centre Hospitalier Universitaire de Besançon (Besançon, França)) ; Mortemousque, Isabelle (Centre Hospitalier Universitaire Bretonneau (Tours, França)) ; McGuffog, Lesley (University of Cambridge. Department of Public Health and Primary Care) ; Chenevix-Trench, Georgia (Queensland Institute of Medical Research (Brisbane, Austràlia)) ; Pereira-Smith, Olivia M. (The University of Texas Health Science Center at San Antonio) ; Nevanlinna, Heli (Helsinki University Central Hospital. Department of Obstetrics and Gynecology (Helsinki, Finlàndia)) ; Hamann, Ute (Deutsches Krebsforschungszentrum (Heidelberg, Alemanya)) ; Torres, Diana (Pontificia Universidad Javeriana. Instituto de Genética Humana (Bogota, Colòmbia)) ; Caligo, Maria Adelaide (University Hospital of Pisa. Section of Genetic Oncology (Pisa, Itàlia)) ; Godwin, Andrew K. (University of Kansas Medical Center. Department of Pathology and Laboratory MedicineCenter (Kansas, Estats Units d'Amèrica)) ; Imyanitov, Evgeny N. (N.N. Petrov Institute of Oncology. Laboratory of Molecular Oncology (Sant Petersburg, Rússia)) ; Janavicius, Ramunas (Vilnius University Hospital Santariskiu Clinics. Hematology, Oncology and Transfusion Medicine Center (Vilnius, Lituània)) ; Sinilnikova, Olga M. (Centre Hospitalier Universitaire de Lyon. Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents (Lyon, França)) ; Stoppa-Lyonnet, Dominique (Institut Curie) ; Mazoyer, Sylvie (Université Lyon 1. Cancer Research Center of Lyon (Lyon, França)) ; Verny-Pierre, Carole (Université Lyon 1. Cancer Research Center of Lyon (Lyon, França)) ; Castera, Laurent (Institut Curie) ; de Pauw, Antoine (Institut Curie) ; Bignon, Yves-Jean (Université de Clermont-Ferrand. Département d'Oncogénétique (Clermont-Ferrand, França)) ; Uhrhammer, Nancy (Université de Clermont-Ferrand. Département d'Oncogénétique (Clermont-Ferrand, França)) ; Peyrat, Jean-Philippe (Centre Oscar Lambret. Laboratoire d'Oncologie Moléculaire Humaine (Lille, França)) ; Vennin, Philippe (Centre Oscar Lambret. Consultation d'Oncogénétique (Lille, França)) ; The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) ; The Netherlands Cancer Institute. Hereditary Breast and Ovarian Cancer Group (HEBON) ; University of Utah School of Medicine. Breast Cancer Family Registry (Salt Lake City, Estats Units d'Amèrica) ; Lund University. Swedish Breast Cancer Study (Lund, Suècia) ; Fédération Nationale des Centres de Lutte Contre le Cancer. Groupe Génétique et Cancer (Lyon, França)
Introduction: Proteins encoded by Fanconi anemia (FA) and/or breast cancer (BrCa) susceptibility genes cooperate in a common DNA damage repair signaling pathway. To gain deeper insight into this pathway and its influence on cancer risk, we searched for novel components through protein physical interaction screens. [...]
2011 - 10.1186/bcr2862
Breast cancer research, Vol. 13, Núm. R40 (4 2011) -14  
8.
7 p, 210.6 KB Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2 : a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry / Salido, Marta (Hospital del Mar (Barcelona, Catalunya). Laboratori de Citogenètica i Biologia Molecular) ; Tusquets Trias de Bes, Ignacio (Universitat Autònoma de Barcelona) ; Corominas Torres, Josep M. (Universitat Autònoma de Barcelona) ; Suárez, Marta (Institut Municipal d'Assistència Sanitària (Barcelona, Catalunya)) ; Espinet i Solà, Blanca (Institut Municipal d'Assistència Sanitària (Barcelona, Catalunya)) ; Corzo Contero, Cristina (Universitat Autònoma de Barcelona) ; Bellet, Meritxell (Institut Municipal d'Assistència Sanitària (Barcelona, Catalunya)) ; Fabregat, Xavier (Institut Municipal d'Assistència Sanitària (Barcelona, Catalunya)) ; Serrano Figueras, S. (Sergio) (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Solé Ristol, Francesc (Hospital del Mar (Barcelona, Catalunya). Laboratori de Citogenètica i Biologia Molecular)
Introduction: One of the most common genetic aberrations associated with breast cancer is the amplification and overexpression of the ERBB2 proto-oncogene located at chromosome 17, bands q12-21. The amplification/overexpression occurs in 25 to 30% of all breast cancers. [...]
2005 - 10.1186/bcr996
Breast cancer research, Vol. 7, N. R267 (January 2005)  
9.
13 p, 4.6 MB A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines / Puig, Teresa (Institut d'Investigació Biomèdica (Girona)) ; Aguilar, Helena (Institut Català d'Oncologia) ; Cufí, Sílvia (Institut d'Investigació Biomèdica (Girona)) ; Oliveras, Glòria (Institut d'Investigació Biomèdica (Girona)) ; Turrado, Carlos (Universidad Complutense de Madrid) ; Ortega Gutiérrez, Silvia (Universidad Complutense de Madrid) ; Benhamú, Bellinda (Universidad Complutense de Madrid) ; López-Rodríguez, María Luz (Universidad Complutense de Madrid) ; Urruticoechea, Ander (Institut Català d'Oncologia) ; Colomer Bosch, Ramón (Centro Oncológico MD Anderson (Madrid))
Introduction: Inhibiting the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of breast carcinoma cells, and this is linked to human epidermal growth factor receptor 2 (HER2) signaling pathways in models of simultaneous expression of FASN and HER2. [...]
2011 - 10.1186/bcr3077
Breast cancer research, Vol. 13, N. R131 (December 2011) , p. 1-13
4 documents
10.
12 p, 436.1 KB Biomarkers characterization of circulating tumour cells in breast cancer patients / Nadal Rios, Rosa (Universitat Autònoma de Barcelona. Departament de Medicina) ; Fernandez, Ana (Universidad de Granada (Granada, Andalusia)) ; Sanchez-Rovira, Pedro (Universidad de Granada (Granada, Andalusia)) ; Salido, Marta (Hospital del Mar (Barcelona, Catalunya)) ; Rodríguez, María (Hospital del Mar (Barcelona, Catalunya)) ; García-Puche, José Luis (Universidad de Granada (Granada, Andalusia)) ; Macià, Marta (Hospital del Mar (Barcelona, Catalunya)) ; Corominas, Josep Maria (Hospital del Mar (Barcelona, Catalunya)) ; Delgado-Rodriguez, Miguel (Universidad de Jaén (Jaén, Andalusia)) ; Gonzalez, Lucas (Universidad de Granada (Granada, Andalusia)) ; Albanell, Joan (Hospital del Mar (Barcelona, Catalunya)) ; Fernández, Mónica (Universidad de Granada (Granada, Andalusia)) ; Solé, Francesc (Universitat Autònoma de Barcelona. Departament de Medicina) ; Lorente, José Antonio (Universidad de Granada (Granada, Andalusia)) ; Serrano, María José (Universidad de Granada (Granada, Andalusia))
Introduction: Increasing evidence supports the view that the detection of circulating tumor cells (CTCs) predicts outcomes of nonmetastatic breast cancer patients. CTCs differ genetically from the primary tumor and may contribute to variations in prognosis and response to therapy. [...]
2012 - 10.1186/bcr3180
Breast cancer research, Vol. 14, N. R71 (May 2012) , p. 1-12  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.